A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Menopause, Multiple Sclerosis

In brief

Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether this medication alleviates menopausal symptoms in women with MS. The investigators will secondarily determine whether addressing menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening inflammation.

Key facts

Study ID

NCT02710214

Run by

University of California, San Francisco

People needed

24

Starts

2016-02-01

Expected to finish

2019-04-24

Last updated by the study team

2020-07-15

Who can join

Age: 18 and older, up to 62. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women aged 40-62 years.
• Perimenopausal: 6 months of amenorrhea; women who had a bi-lateral oophorectomy; women without a uterus and who still have one or both ovaries, with FSH level > 20 mIU/mL and estradiol ≤ 50 pg/mL; women with a uterus who have skipped 2 or more menstrual cycles with an amenorrhea interval; women who are using the Mirena IUD or who have had an endometrial ablation and who still have one or both ovaries, with FSH level > 20 mIU/mL and estradiol ≤ 50 pg/mL
• Bothersome MS symptoms: Mean of two or more hot flashes/night sweats per 24 hrs; Hot flashes/night sweats rated as bothersome ('moderately' to 'a lot') and/or severe ('moderate' to 'severe') on 4 or more 12 hour (day/night) blocks of times
• In general good health (determined by medical history, blood pressure, and heart rate)
• No history of endometrial, ovarian, or breast cancer; No abnormal mammogram in the last 2 years; Absence of any current severe or unstable medical illness
• MS considerations:
• If using psychotropic medications: no change in the past 3 months
• If on DMT, no change in past 6 months Normal vitamin D levels (20-50 ng/mL)

You may not qualify if…

• BMI >35 kg/m2 as higher BMI may affect PK/PD
• Use of hormone therapy or hormonal contraceptives 2 months prior to enrollment
• Use of any prescribed therapy that is taken specifically for hot flashes in the past 1 month.
• Use of any over-the-counter or herbal therapies that are taken specifically for hot flashes in the past 2 weeks.
• Use of selective estrogen receptor modulators (SERMs) or aromatase inhibitors during the 2 months before enrollment.
• Known hypersensitivity or contraindications to estrogen.
• Drug or alcohol abuse in the past 1 year
• Depression: moderate or severe (HAD score > 8) Other psychiatric disease meeting DSM-IV criteria
• Lifetime diagnosis of psychosis or bipolar disorder.
• Pregnancy, intending pregnancy, or breast feeding
• History of any of the following, as determined by clinician review of the potential participant's medical history:
• Pre-breast cancer or high-risk breast cancer condition;
• Abnormal bleeding suggestive of endometrial pre-cancer;
• Endometrial hyperplasia;
• Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable or under medical management;
• Active or past history of venous or arterial thromboembolism
• History of gallstones IF gallbladder intact
• Known or suspected estrogen-dependent neoplasia
• History of coronary artery disease
• Hypersensitivity (angioedema, anaphylaxis) to estrogens, bazedoxifene, or any ingredients
• Known hepatic impairment or disease
• Thyroid dysfunction on thyroid medications
• Known hypoparathyroidism
• Blood test results indicating:
• Liver function tests: AST >2.5 times upper limit of normal; ALT >2.5 times upper limit of normal; total bilirubin 1.5 times upper limit of normal;

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.